Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) was up 17.1% during trading on Tuesday . The company traded as high as $0.48 and last traded at $0.48. Approximately 876,335 shares were traded during mid-day trading, an increase of 87% from the average daily volume of 469,853 shares. The stock had previously closed at $0.41.

A number of equities research analysts have commented on DFFN shares. HC Wainwright restated a “buy” rating and issued a $1.25 target price on shares of Diffusion Pharmaceuticals in a research report on Monday, August 20th. ValuEngine upgraded Diffusion Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, June 2nd.

The company has a market cap of $24.12 million, a price-to-earnings ratio of -0.41 and a beta of -1.75.

Diffusion Pharmaceuticals (NASDAQ:DFFN) last issued its quarterly earnings data on Monday, August 13th. The company reported ($0.05) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.06) by $0.01. analysts predict that Diffusion Pharmaceuticals Inc will post -0.42 EPS for the current fiscal year.

A hedge fund recently raised its stake in Diffusion Pharmaceuticals stock. Swift Run Capital Management LLC grew its position in Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) by 261.8% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,508,017 shares of the company’s stock after buying an additional 1,814,806 shares during the quarter. Diffusion Pharmaceuticals accounts for 1.0% of Swift Run Capital Management LLC’s holdings, making the stock its 23rd largest holding. Swift Run Capital Management LLC owned approximately 4.96% of Diffusion Pharmaceuticals worth $1,369,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 7.63% of the company’s stock.

About Diffusion Pharmaceuticals (NASDAQ:DFFN)

Diffusion Pharmaceuticals Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer. Its lead product candidate is transcrocetinate sodium, which has initiated Phase 3 trials for the treatment of glioblastoma multiforme (GBM); Phase 2 clinical trials for the treatment of pancreatic cancer; Phase 2/3 clinical trials for the treatment of metastatic brain cancer; and Phase 2 trial for the treatment of stroke.

Featured Story: Closed-End Mutual Funds (CEFs)

Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.